Gilead Sciences, Emirates Oncology Society sign cancer research deal
UAE – Gilead Sciences, Inc., a renowned research-based biopharmaceutical company, has struck a strategic partnership with the Emirates Oncology Society (EOS) to drive cancer research in the United Arab Emirates.
The pivotal Memorandum of Understanding (MoU) was signed by Vitor Papao, General Manager of Middle East at Gilead Sciences, and Professor Dr. Humaid Al-Shamsi, the President of the Emirates Oncology Society.
Through a shared commitment to transform the healthcare landscape, Gilead Sciences and Emirates Oncology Society will work closely to elevate patient care, improve patient outcomes, and accelerate innovation in oncology in the UAE.
The non-promotional partnership will focus on four key areas, including education, research, awareness, and optimized treatment management.
In a press release, Prof. Dr. Humaid Al-Shamsi, President of the Emirates Oncology Society, said: “By joining forces with Gilead Sciences, we aim to bolster our capabilities by harnessing their invaluable expertise and vast resources.”
Under the terms of the oncology deal, Gilead Sciences will spearhead the exchange of cutting-edge scientific and educational information to empower healthcare professionals with the latest knowledge to advance patient care.
Gilead Sciences and Emirates Oncology Society will also jointly launch disease awareness campaigns, in particular, initiatives focused on breast cancer, bladder cancer, and key areas of oncology and hematology.
The emirate-wide awareness campaigns will soon kick-start with an emphasis on increasing understanding of early cancer warning signs to halt disease progression and improve patient outcomes.
The main objective of industry-academia collaboration is to improve healthcare and enhance outcomes for cancer patients throughout the United Arab Emirates.
Additionally, the support from Gilead Sciences will revitalize EOS’s efforts to equip cancer specialists with the latest scientific knowledge and technology available.
Underlining the vision of EOS, Dr. Humaid Al-Shamsi reflected: “We are dedicated to fostering effective collaboration with key stakeholders to provide the highest level of healthcare and deliver the best possible patient experience to society.”
Strikingly, the partnership between Gilead Sciences and Emirates Oncology Society comes as part of EOS’s moral vision to provide its members with cutting-edge information to make a lasting impact on the lives of cancer patients in the UAE.
This joint venture stands as a testament to the Emirates Oncology Society’s dedication to promoting and foster the multidimensional care of cancer patients throughout the United Arab Emirates.
EOS brings together practicing cancer specialists across all disciplines including physicians, surgeons, radiation therapists, oncology nurses, social workers, pharmacists, cancer researchers, and dietitians.
Consequently, the partnership between Gilead Sciences and EOS will pave the way for the provision of comprehensive educational materials to guide audiences towards specialized healthcare professionals.
The new deal is based purely on the biopharmaceutical company’s commitment to the advancement of innovative medicines to prevent and treat life-threatening diseases including cancer.
On his part, Vitor Papao, General Manager of Middle East at Gilead Sciences, stated: “Our strategic partnership with EOS showcases our commitment to fostering a healthier world for all by facilitating the sharing of scientific advancements, including vital clinical data and best healthcare practices.”
Gilead Sciences, Inc. has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
By joining forces with the Emirates Oncology Society, Gilead Sciences aims to make a lasting impact on the lives of oncology patients and propel advancements in cancer treatments throughout the UAE.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
Be the first to leave a comment